ATE462437T1 - Krebstherapie mit ganzen glukan-teilchen und antikörpern - Google Patents
Krebstherapie mit ganzen glukan-teilchen und antikörpernInfo
- Publication number
- ATE462437T1 ATE462437T1 AT03749452T AT03749452T ATE462437T1 AT E462437 T1 ATE462437 T1 AT E462437T1 AT 03749452 T AT03749452 T AT 03749452T AT 03749452 T AT03749452 T AT 03749452T AT E462437 T1 ATE462437 T1 AT E462437T1
- Authority
- AT
- Austria
- Prior art keywords
- glucan particles
- whole glucan
- antibodies
- cancer therapy
- immune system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40812602P | 2002-09-04 | 2002-09-04 | |
PCT/US2003/027841 WO2004021994A2 (en) | 2002-09-04 | 2003-09-04 | Cancer therapy using whole glucan particles and antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE462437T1 true ATE462437T1 (de) | 2010-04-15 |
Family
ID=31978563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03749452T ATE462437T1 (de) | 2002-09-04 | 2003-09-04 | Krebstherapie mit ganzen glukan-teilchen und antikörpern |
Country Status (9)
Country | Link |
---|---|
US (3) | US8883760B2 (de) |
EP (3) | EP2181711A1 (de) |
JP (1) | JP2006502167A (de) |
CN (3) | CN1939335A (de) |
AT (1) | ATE462437T1 (de) |
AU (2) | AU2003268486A1 (de) |
CA (2) | CA2496508C (de) |
DE (1) | DE60331925D1 (de) |
WO (2) | WO2004021994A2 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
EP1545208A4 (de) | 2002-08-13 | 2006-04-12 | Biopolymer Engineering Inc | Verfahren zur verwendung von beta-glucan als strahlenschutzmittel |
EP2181711A1 (de) | 2002-09-04 | 2010-05-05 | Biopolymer Engineering, Inc. | Krebstherapie mit ganzen Glukan-Teilchen und Antikörpern |
US20060165700A1 (en) * | 2002-09-04 | 2006-07-27 | Ostroff Gary R | Cancer therapy using whole glucan particles and antibodies |
US20080260742A1 (en) | 2004-04-09 | 2008-10-23 | Takeda Pharmaceutical Company Limited | Preventives/Remedies for Cancer |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
JP5302537B2 (ja) | 2004-09-17 | 2013-10-02 | ユニバーシティ オブ マサチューセッツ | リソソーム酵素欠損症のための組成物およびそれらの使用 |
EP1917019A2 (de) * | 2005-05-03 | 2008-05-07 | Biopolymer Engineering, Inc. | Kombination eines beta-glucans und eines egf-rezeptor-antagonisten zur krebs- und infektionsbehandlung |
US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
US8323644B2 (en) | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
WO2007084661A2 (en) * | 2006-01-17 | 2007-07-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
RU2490279C2 (ru) | 2006-06-15 | 2013-08-20 | Байотера, Инк. | Композиции глюкана |
CN101528245A (zh) * | 2006-08-24 | 2009-09-09 | 麒麟控股株式会社 | 用于改善皮肤状态的组合物 |
WO2008027580A2 (en) * | 2006-09-01 | 2008-03-06 | University Of Louisville | PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS |
US20080063650A1 (en) * | 2006-09-01 | 2008-03-13 | Jun Yan | mCRP antagonists and their uses |
EP2066294B9 (de) * | 2006-11-06 | 2013-04-10 | Whitehead Institute | Immunmodulierende zusammensetzungen und verfahren zu ihrer verwendung |
US9457047B2 (en) | 2006-11-06 | 2016-10-04 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
WO2009058913A2 (en) | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
WO2009103116A1 (en) * | 2008-02-19 | 2009-08-27 | Novogen Research Pty Ltd | Ex vivo cell stimulation |
WO2009103115A1 (en) * | 2008-02-19 | 2009-08-27 | Novogen Research Pty Ltd | Evaluating the therapeutic potential of a glucan |
WO2013040027A1 (en) * | 2011-09-12 | 2013-03-21 | Baylor Research Institute | Reprogramming immune environment in breast cancer via dendritic cells |
EP3373006A1 (de) * | 2012-04-30 | 2018-09-12 | Biothera, Inc. | Immuntherapieverfahren mit beta-glucan |
CA2873026C (en) | 2012-05-07 | 2021-01-12 | Algal Scientific Corporation | Multi-stage process for production of immune modulator |
US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
US9738731B2 (en) * | 2013-03-08 | 2017-08-22 | Tokyo University Of Science Foundation | Lactic acid bacterium growth enhancer, regulatory T-cell number increasing agent, method of enhancing growth of lactic acid bacterium, method of increasing number of regulatory T-cells, method of evaluating regulatory T-cell number increasing effect, and method of evaluating lactic acid growth enhancing effect |
EP2832360A1 (de) | 2013-07-30 | 2015-02-04 | Fresenius Kabi Deutschland GmbH | Polysaccharid zur Verwendung bei der Prävention der Bildung von Metastasen und/oder Rezidiven |
US9885726B2 (en) * | 2013-12-05 | 2018-02-06 | Biothera, Inc. | β-glucan assay methods |
US10166195B2 (en) | 2014-03-05 | 2019-01-01 | Orbis Health Solutions, Llc | Vaccine delivery systems using yeast cell wall particles |
LT6145B (lt) | 2014-04-14 | 2015-04-27 | Uab "Biocentras" | TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ |
ES2877099T3 (es) | 2014-07-10 | 2021-11-16 | Hibercell Inc | Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral |
CN107106593B (zh) | 2014-11-06 | 2021-05-07 | 百奥赛诺公司 | 影响肿瘤微环境的β-葡聚糖方法与组合物 |
US20180110853A1 (en) * | 2016-10-21 | 2018-04-26 | Wisconsin Alumni Research Foundation | Vaccine Adjuvant |
JP2019536811A (ja) * | 2016-12-07 | 2019-12-19 | イネイト バイオセラピューティクス, エルエルシー | β−1,6−グルカンのトラスツズマブ抗体コンジュゲート |
EP3582810A4 (de) | 2016-12-07 | 2020-08-19 | Innate Biotherapeutics, LLC | ß-1,6-GLUCAN-THERAPEUTISCHE ANTIKÖRPERKONJUGATE |
US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
AU2018251694B2 (en) | 2017-04-10 | 2020-06-11 | Kibow Biotech Inc. | Multifiber prebiotic composition for digestive health, weight control, boosting immunity and improving health |
US20210283168A1 (en) * | 2018-03-13 | 2021-09-16 | Hibercell, Inc. | Beta glucan and cd40 agonist combination immunotherapy |
US20220265698A1 (en) * | 2019-09-11 | 2022-08-25 | Aureo Co., Ltd. | Composition for enhancing effect of antibody drug |
EP3858362A1 (de) | 2020-01-29 | 2021-08-04 | Pleuran, s.r.o. | Beta-glucan zur verwendung bei der verbesserung der anti-tumor-immunität bei remission |
US20230045997A1 (en) * | 2020-01-29 | 2023-02-16 | Pleuran, S.R.O. | Beta-glucan for use in modulation of an immune response in a remission |
WO2022251123A1 (en) * | 2021-05-24 | 2022-12-01 | Frank Jordan | Alkaline extraction of beta glucan compounds for use in anti-viral and immune therapies |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943247A (en) | 1972-05-22 | 1976-03-09 | Kaken Kagaku Kabushiki Kaisha | Treatment of bacterial infections with glucan compositions |
US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
US4138479A (en) | 1975-11-07 | 1979-02-06 | Bayer Aktiengesellschaft | Process for the preparation of immunopotentiating agents from components of yeast cell wall material |
JPS5461112A (en) | 1977-10-24 | 1979-05-17 | Ono Pharmaceut Co Ltd | Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component |
JPS58220989A (ja) | 1982-06-14 | 1983-12-22 | Diesel Kiki Co Ltd | 可変容量式ベ−ン型圧縮機 |
SE456911B (sv) | 1983-12-19 | 1988-11-14 | Olle Larm | Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma |
US5037972A (en) | 1984-11-28 | 1991-08-06 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5028703A (en) | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5082936A (en) | 1984-11-28 | 1992-01-21 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US4810646A (en) | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
US4992540A (en) | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5250436A (en) | 1984-11-28 | 1993-10-05 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
CA1340080C (en) | 1985-03-11 | 1998-10-13 | Dorothee Herlyn | Human tumor therapy |
US4975421A (en) | 1985-08-19 | 1990-12-04 | Bioglucan, Lp. | Soluble phosphorylated glucan: methods and compositions for wound healing |
US4739046A (en) | 1985-08-19 | 1988-04-19 | Luzio Nicholas R Di | Soluble phosphorylated glucan |
US4900722A (en) | 1985-08-19 | 1990-02-13 | Bioglucans, L.P. | Methods and compositions for prophylactic and therapeutic treatment of infections |
US5221616A (en) * | 1988-07-15 | 1993-06-22 | Quidel Corporation | Prevention of spontaneous complement activation in mammalian biological fluids |
KR0141685B1 (ko) | 1988-09-01 | 1998-07-01 | 야마따니 와따루 | 참게 아메보사이트 라이세이트 g 인자 활성화 저해제 |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5057503A (en) | 1989-01-23 | 1991-10-15 | The Brigham And Women's Hospital | Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor |
CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
US4946450A (en) | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
IT1232310B (it) | 1989-09-04 | 1992-01-28 | Consiglio Nazionale Ricerche | Processo per la preparazione di un prodotto contenente glucano a partire da candida albicans bmm-12 |
JPH05503952A (ja) | 1989-09-08 | 1993-06-24 | アルファ ベータ テクノロジー,インコーポレイティッド | 可溶性グルカン類の製造方法 |
US5488040A (en) | 1989-09-08 | 1996-01-30 | Alpha-Beta Technology, Inc. | Use of neutral soluble glucan preparations to stimulate platelet production |
US5811542A (en) | 1989-09-08 | 1998-09-22 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
EP0491829B1 (de) | 1989-09-08 | 1997-06-04 | Alpha Beta Technology, Inc. | Zusammensetzung zur Stimulierung des Immunsystems |
US5622939A (en) * | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
US5223491A (en) | 1989-11-09 | 1993-06-29 | Donzis Byron A | Method for revitalizing skin by applying topically water insoluble glucan |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JP2911554B2 (ja) | 1990-06-25 | 1999-06-23 | 台糖株式会社 | 抗ウィルス剤 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JP3122454B2 (ja) | 1990-09-27 | 2001-01-09 | 生化学工業株式会社 | カブトガニ・アメボサイト・ライセートの調製法 |
EP0564531B1 (de) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
EP0580737B1 (de) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
IT1256035B (it) | 1992-08-10 | 1995-11-21 | Consiglio Nazionale Ricerche | Glucani ad attivita' immunostimolante |
US5453124A (en) | 1992-12-30 | 1995-09-26 | Texas Instruments Incorporated | Programmable multizone gas injector for single-wafer semiconductor processing equipment |
US5622940A (en) | 1994-07-14 | 1997-04-22 | Alpha-Beta Technology | Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan |
GB9420645D0 (en) * | 1994-10-13 | 1994-11-30 | Dow Chemical Co | Non-linear stytrenic polymer compositions and articles prepared therefrom |
US5576015A (en) | 1995-03-02 | 1996-11-19 | Donzis; Byron A. | Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses |
AUPN166195A0 (en) | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
US6036946A (en) | 1997-12-24 | 2000-03-14 | Shaklee Corporation | Methods for protecting skin from damaging effects of ultraviolet light |
DE69940371D1 (de) | 1998-09-14 | 2009-03-19 | Nabi Biopharmaceuticals Rockvi | Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline |
US6369216B1 (en) | 1998-09-25 | 2002-04-09 | Biopolymer Engineering Pharmaceutical, Inc. | Very high molecular weight β-glucans |
CA2434938C (en) | 2001-01-16 | 2012-02-28 | Sloan-Kettering Institute For Cancer Research | Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7786094B2 (en) * | 2001-10-09 | 2010-08-31 | Biopolymer Engineering, Inc. | Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
EP1545208A4 (de) | 2002-08-13 | 2006-04-12 | Biopolymer Engineering Inc | Verfahren zur verwendung von beta-glucan als strahlenschutzmittel |
US20060165700A1 (en) | 2002-09-04 | 2006-07-27 | Ostroff Gary R | Cancer therapy using whole glucan particles and antibodies |
EP2181711A1 (de) * | 2002-09-04 | 2010-05-05 | Biopolymer Engineering, Inc. | Krebstherapie mit ganzen Glukan-Teilchen und Antikörpern |
US20090169557A1 (en) | 2004-05-10 | 2009-07-02 | Biopolymer Engineering, Inc. D/B/A Biothera | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies |
-
2003
- 2003-09-04 EP EP10001786A patent/EP2181711A1/de not_active Withdrawn
- 2003-09-04 CN CNA2006101362698A patent/CN1939335A/zh active Pending
- 2003-09-04 CA CA2496508A patent/CA2496508C/en not_active Expired - Lifetime
- 2003-09-04 CN CNB038248956A patent/CN100363054C/zh not_active Ceased
- 2003-09-04 CA CA2496596A patent/CA2496596C/en not_active Expired - Fee Related
- 2003-09-04 US US10/526,185 patent/US8883760B2/en active Active
- 2003-09-04 DE DE60331925T patent/DE60331925D1/de not_active Expired - Lifetime
- 2003-09-04 EP EP03786508A patent/EP1539194A4/de not_active Ceased
- 2003-09-04 EP EP03749452.3A patent/EP1536820B2/de not_active Expired - Lifetime
- 2003-09-04 WO PCT/US2003/027841 patent/WO2004021994A2/en active Application Filing
- 2003-09-04 AU AU2003268486A patent/AU2003268486A1/en not_active Abandoned
- 2003-09-04 JP JP2004534637A patent/JP2006502167A/ja active Pending
- 2003-09-04 AU AU2003295326A patent/AU2003295326A1/en not_active Abandoned
- 2003-09-04 AT AT03749452T patent/ATE462437T1/de not_active IP Right Cessation
- 2003-09-04 CN CN03824893XA patent/CN1694715B/zh not_active Expired - Lifetime
- 2003-09-04 WO PCT/US2003/027975 patent/WO2004030613A2/en not_active Application Discontinuation
-
2014
- 2014-10-30 US US14/528,900 patent/US9522187B2/en not_active Expired - Lifetime
-
2016
- 2016-11-10 US US15/348,057 patent/US20170056432A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9522187B2 (en) | 2016-12-20 |
CA2496596C (en) | 2016-06-28 |
CA2496508C (en) | 2014-04-22 |
EP1539194A4 (de) | 2007-06-13 |
EP1539194A2 (de) | 2005-06-15 |
CN1697659A (zh) | 2005-11-16 |
CN1694715A (zh) | 2005-11-09 |
US20150064199A1 (en) | 2015-03-05 |
DE60331925D1 (de) | 2010-05-12 |
WO2004030613A2 (en) | 2004-04-15 |
US20170056432A1 (en) | 2017-03-02 |
CA2496508A1 (en) | 2004-04-15 |
JP2006502167A (ja) | 2006-01-19 |
EP1536820B2 (de) | 2013-10-23 |
WO2004021994A2 (en) | 2004-03-18 |
EP1536820A2 (de) | 2005-06-08 |
CA2496596A1 (en) | 2004-03-18 |
WO2004030613A3 (en) | 2005-01-13 |
CN1939335A (zh) | 2007-04-04 |
CN100363054C (zh) | 2008-01-23 |
CN1694715B (zh) | 2010-12-01 |
US8883760B2 (en) | 2014-11-11 |
AU2003295326A1 (en) | 2004-04-23 |
EP2181711A1 (de) | 2010-05-05 |
AU2003268486A1 (en) | 2004-03-29 |
EP1536820A4 (de) | 2007-06-20 |
AU2003295326A8 (en) | 2004-04-23 |
EP1536820B1 (de) | 2010-03-31 |
AU2003268486A8 (en) | 2004-03-29 |
US20060009419A1 (en) | 2006-01-12 |
WO2004021994A3 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60331925D1 (de) | Krebstherapie mit ganzen glukan-teilchen und antikörpern | |
WO2005081854A3 (en) | Egf receptor epitope peptides and uses thereof | |
MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
PL2135881T3 (pl) | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu | |
WO2008070042A3 (en) | High potency recombinant antibodies, methods for producing them and use in cancer therapy | |
WO2003106498A3 (en) | HUMAN OX40 RECEPTOR AGONIST BINDING MOLECULES | |
AU2019415848A8 (en) | Claudin18.2 binding moieties and uses thereof | |
BRPI0515604A (pt) | método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada | |
MX356367B (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. | |
NO20016007D0 (no) | Rekombinant anti-CD40-antistoff og anvendelser derav | |
WO2006085895A3 (en) | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies | |
TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
WO2011070214A8 (es) | Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral | |
IL188594A0 (en) | Anti-ccr7 receptor antibodies for the treatment of cancer | |
MX2021002605A (es) | Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer. | |
DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
MX2019000135A (es) | Anticuerpos anti-transicion mesenquimal-epitelial (met) y usos de los mismos. | |
MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
MX2022004086A (es) | Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos. | |
WO2007144046A3 (de) | Mittel zur behandlung von malignen erkrankungen | |
ATE271871T1 (de) | Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden | |
ATE536887T1 (de) | Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |